Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26750619 | 0.89 | HTT (0.45) | TSHRHSD17B10CYP3A4ALDH1A1MAPT | |
| SCHEMBL29316594 | 0.89 | HTT (0.45) | TSHRHSD17B10CYP3A4ALDH1A1MAPT | |
| SCHEMBL26743067 | 0.89 | HTT (0.45) | TSHRHSD17B10CYP3A4ALDH1A1MAPT | |
| SCHEMBL29328253 | 0.85 | ALDH1A1 (0.38) | CYP3A4ALDH1A1SIGMAR1MEN1POLB | |
| SCHEMBL26743858 | 0.84 | SLC6A4 (0.36) | ALDH1A1HTTSIGMAR1MEN1KMT2A | |
| SCHEMBL26741504 | 0.82 | CHRM5 (0.42) | TSHRHSD17B10CYP3A4ALDH1A1CYP2C19 | |
| SCHEMBL26744000 | 0.82 | CHRM5 (0.42) | TSHRHSD17B10CYP3A4ALDH1A1CYP2C19 | |
| SCHEMBL29316576 | 0.82 | CHRM5 (0.42) | TSHRHSD17B10CYP3A4ALDH1A1CYP2C19 | |
| SCHEMBL29323594 | 0.81 | SIGMAR1 (0.42) | TSHRHSD17B10CYP3A4ALDH1A1MAPT | |
| SCHEMBL26741473 | 0.81 | CHRM5 (0.48) | TSHRHSD17B10CYP3A4ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | TSHR 4074/4885HSD17B10 818/4885CYP3A4 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.